Drug Profile
Research programme: small molecule therapeutics - Infinity/Johnson & Johnson
Latest Information Update: 16 Mar 2009
Price :
$50
*
At a glance
- Originator Infinity Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 31 Dec 2008 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
- 14 Mar 2007 Infinity Pharmaceuticals has recognised $US1 million revenue from delivery of compounds to Johnson & Johnson under this agreement
- 31 Dec 2005 Infinity has amended the agreement to allow for a reduction in the number of compounds to be delivered to Johnson & Johnson